This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

This study has been completed.
Information provided by:
Alza Corporation, DE, USA Identifier:
First received: September 15, 2005
Last updated: May 18, 2011
Last verified: March 2010
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).

Condition Intervention Phase
Ejaculation Drug: Dapoxetine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation

Further study details as provided by Alza Corporation, DE, USA:

Primary Outcome Measures:
  • Average intravaginal ejaculatory latency time (IELT), as measured by stopwatch during sexual intercourse, between last 2 visits during the treatment period

Secondary Outcome Measures:
  • Control over ejaculation, satisfaction with sexual intercourse, and severity of symptom impressions, based on questions asked at start of study and through Week 12; incidence, severity, and type of adverse events throughout study (12 weeks).

Enrollment: 1294
Study Start Date: June 2003
Study Completion Date: June 2004
Detailed Description:
One form of male sexual dysfunction is premature ejaculation (PE), which is also referred to as rapid ejaculation (RE). An objective measurement of PE in clinical studies is the intravaginal ejaculatory latency time (IELT). This is a randomized, double-blind study in men with PE. The study consists of 2 phases: pre-randomization phase (a screening visit and a 2-week baseline period); 12-week double-blind treatment phase during which patients will receive dapoxetine at one of two dosages, or placebo, for use on an "as-needed" basis. The total duration of the study is approximately 14 weeks. Patients and their partners are expected to attempt sexual intercourse at least 4 times during the baseline period and at least 6 times each month during the treatment phase. Assessments of effectiveness include the average Intravaginal Ejaculatory Latency time (IELT), as measured by stopwatch, during sexual intercourse for the treatment period (12 weeks); control over ejaculation, satisfaction with sexual intercourse, and severity of symptoms, based on questions asked at monthly intervals through the treatment phase. Safety assessments include the incidence, severity, and type of adverse events throughout treatment (12 weeks), vital sign measurements (pulse and blood pressure) and laboratory tests (hematology, chemistry, urinalysis) at monthly intervals. The study hypothesis is that treatment for 12 weeks with dapoxetine prolongs intravaginal ejaculatory latency time, compared with placebo, in men with PE. Oral tablets of dapoxetine (30 milligrams[mg] or 60mg) taken as needed during 12 weeks of treatment. No more than one dose within a 24-hour period.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Heterosexual male in a stable, monogamous, sexual relationship with a female partner for at least 6 months
  • onset of orgasm and ejaculation occurs with minimal sexual stimulation before or shortly after penetration and before the person wishes it
  • premature ejaculation (PE) in the majority of intercourse experiences in the 6 months before study initiation
  • intravaginal latency ejaculatory time (IELT) of <=2 minutes in at least 3 out of 4 events
  • participants with partners of child-bearing potential must consent to use a medically acceptable method of contraception throughout the entire study
  • participant's partner must have a negative pregnancy test at time of screening.

Exclusion Criteria:

  • History of surgery or injury to the pelvis or spinal cord, chronic inflammation of the prostate or urethra
  • taking medications that are contraindicated for participation in the study
  • currently using other forms of therapy for treatment of PE (for example, behavioral therapy or medications applied locally)
  • previously participated in a drug study involving dapoxetine or in another drug trial within the last month
  • taken pimozide, astemizole, or monoamine oxidase inhibitors within 6 months of the start of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00211107

Sponsors and Collaborators
Alza Corporation, DE, USA
Study Director: Alza Corporation Clinical Trial ALZA
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00211107     History of Changes
Other Study ID Numbers: CR006088
Study First Received: September 15, 2005
Last Updated: May 18, 2011

Keywords provided by Alza Corporation, DE, USA:
rapid ejaculation
premature ejaculation
sexual dysfunction
orgasmic disorder
sexual intercourse

Additional relevant MeSH terms:
Premature Ejaculation
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders processed this record on August 16, 2017